Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.52 | N/A | -4.00% |
management commentary, guidance changes, and full analysis available with Pro.
| -4.00% |
Tone: Defensive
Management expressed concerns about the current financial performance and the path to profitability. They acknowledged the challenges ahead.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in research and development.
Ionis Pharmaceuticals reported a loss that was slightly worse than expected, leading to a notable drop in stock price. The lack of revenue figures and guidance adds uncertainty for investors. The market reacted negatively, reflecting concerns about the company's financial health and future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Haemonetics Corporation